The global osteoporosis drugs market size was valued at USD 14.90 billion in 2024 and is projected to reach USD 15.39 billion ...

Implementing opportunistic computed tomography (CT) bone density screening could increase the osteoporosis screening rate, yielding a reduction in medical costs.

The FDA approved Stoboclo and Osenvelt, denosumab biosimilars that could offer more affordable treatment options for ...

Women with osteoporosis have at least a 50% chance of reaching their target bone mineral density at 3 years if they have a BMD T-score of at least –2.8 at the total hip or –3.1 at the lumbar spine at ...

Alendronate has been shown to increase bone mineral density (BMD) and decrease fracture risk in postmenopausal women with osteoporosis, but the need for long-term treatment is unclear, especially ...

Should you take a calcium supplement? And if so, how much? Here's what to know about calcium's benefits and some warnings.

The "Osteoporosis_Global Clinical Trials Review, 2025" clinical trials has been added to ResearchAndMarkets.com's offering.The clinical trial report provides an overview of Osteoporosis Clinical ...

The FDA has approved Stoboclo (denosumab-bmwo), a biosimilar to Prolia (denosumab), and Osenvelt (denosumab-bmwo), a biosimilar to Xgeva (denosumab).

A new study published in the journal of BMC Gasteroenterology found that patients with the liver cirrhosis had higher risk of ...